By blocking TGF-β signaling in combination with inhibition of the C-X-C motif chemokine receptor 2 (CXCR2), we reported a significant reduction in neutrophil migration toward TCM from the aggressive breast cancer cell line MCF10CA1a (M4) [25]. This evidence concerns the gene CXCR2 and breast carcinoma.